<DOC>
	<DOCNO>NCT00001272</DOCNO>
	<brief_summary>This Phase I study address feasibility toxicity add taxol two drug combination comprise standard care newly diagnose advanced stage ovarian cancer , cisplatin cyclophosphamide . These drug give dose intensive fashion colony-stimulating factor , G-CSF . Newly diagnose patient ovarian cancer treat regimen determine optimal dose combination . The pharmacokinetics taxol cisplatin DNA-adducts study well .</brief_summary>
	<brief_title>A Phase I Study Taxol , Cisplatin , Cyclophosphamide Granulocyte Colony-Stimulating Factor ( G-CSF ) Previously Nontreated Ovarian Cancer Patients</brief_title>
	<detailed_description>This Phase I study address feasibility toxicity add taxol two drug combination comprise standard care newly diagnose advanced stage ovarian cancer , cisplatin cyclophosphamide . These drug give dose intensive fashion colony-stimulating factor , G-CSF . Newly diagnose patient ovarian cancer treat regimen determine optimal dose combination . The pharmacokinetics taxol cisplatin DNA-adducts study well .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>All patient must biopsy proven ovarian cancer determine evaluation Laboratory Pathology , NCI . Germ cell borderline histology specifically exclude . Patients must FIGO stage III IV disease , FIGO Stage IIC disease poorly differentiate histology , undergo attempted surgical debulking prior initiation chemotherapy . Prior chemotherapy radiation therapy make patient ineligible . Performance status : le equal ECOG 2 . Patients must follow end organ function : No brain involvement . No history myocardial infarction , cardiac arrhythmia require therapy , right bundle branch block leave anterior hemiblock , leave bundle branch block . Renal function : creatinine clearance great equal 60 cc/min ; patient ureteral obstruction must correct prior start therapy . Hepatic function : normal coagulation parameter , serum transaminase within 3 time upper limit normal . Neurologic function : preexisting dysfunction great grade 1 ( exclusive mild vibratory delay ) . No recent history active GI bleeding . Hematologic parameter prior start cycle 1 therapy : total granulocyte count great 2000 platelet count great 100,000 . Patients may prior history invasive malignancy exception nonmelanoma skin cancer curatively treat . Patients must able give write informed consent express willingness meet expect requirement protocol . Patients must able begin therapy within 8 week stag laparotomy central venous catheter place infusion chemotherapy . All patient must register call Orkand Corporation 4021732 hour 8:30 AM 5:00 PM ; eligibility criterion query .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 1999</verification_date>
	<keyword>Adult</keyword>
	<keyword>Cytotoxic Chemotherapy</keyword>
	<keyword>Hematopoietic Growth Factor</keyword>
</DOC>